STOCKHOLM, SWEDEN--(MARKET WIRE)--Mar 4, 2008 -- Biovitrum AB (publ), Sweden, and Syntonix Pharmaceuticals, Inc., USA, have obtained approval from the US Food and Drug Administration to commence a clinical phase I/IIa study of a long-acting, recombinant Factor IXFc for the treatment of Hemophilia B.
